Sell-rated reports

287 tickers rated Sell
NewestHighest Score Ranks all reports in this rating group by score, highest first.
Summit Therapeutics Inc.
SMMT·Healthcare
C ★★Sell
Current$17.83
Nov 11, 2026

Ivonescimab's differentiated PD-1/VEGF design, expanding Phase III pipeline and $2.0B AstraZeneca investment create substantial oncology upside, but the pivotal U.S. approval faces an OS-evidence hurdle and meaningful dilution remains.

Score
62
TELUS Corporation
TU·Communication Services
C ★★Sell
Current$9.11
Nov 9, 2026

TELUS owns valuable Canadian wireless and fibre networks with recovery potential from cost savings and debt reduction, but heavy leverage, declining profitability and uncertain asset monetizations undermine its near-term investment appeal.

Score
62
Guardant Health, Inc.
GH·Healthcare
C ★★Sell
Current$150.87
Nov 8, 2026

Guardant Health could become a major beneficiary of expanding blood-based cancer screening and precision oncology, but its demanding valuation, persistent cash burn, and unproven operating leverage create substantial investment risk.

Score
62
Peloton Interactive, Inc.
PTON·Consumer Discretionary
C ★★Sell
Current$5.61
Nov 8, 2026

Peloton's strong cash-flow recovery and improving balance sheet support its turnaround potential, but persistent subscriber losses and shareholder dilution undermine confidence in durable per-share earnings growth.

Score
62
Consolidated Edison, Inc.
ED·Utilities
C ★★Sell
Current$118.56
Nov 8, 2026

Consolidated Edison offers highly defensible regulated utility earnings and a reliable dividend history, but demanding valuation, persistent negative free cash flow, and ongoing equity issuance constrain investment attractiveness.

Score
62
LivaNova PLC
LIVN·Healthcare
C ★★Sell
Current$89.99
Nov 7, 2026

LivaNova benefits from durable cardiac-surgery and neurostimulation franchises with improving earnings and new-product potential, but demanding valuation and substantial legal liabilities constrain its risk-adjusted appeal.

Score
62
Keurig Dr Pepper Inc.
KDP·Consumer Staples
C ★★Sell
Current$36.89
Nov 6, 2026

Keurig Dr Pepper combines durable beverage brands and potential separation value, but heavy acquisition financing and uncertain post-separation cash-flow economics constrain the investment case.

Score
62
Hagerty, Inc.
HGTY·Financials
C ★★Sell
Current$18.36
Nov 6, 2026

Hagerty's differentiated specialty insurance franchise and improving underwriting economics support long-term growth, but elevated valuation multiples and increased claims-risk exposure limit the investment appeal.

Score
62
Mobileye Global Inc.
MBLY·Consumer Discretionary
C ★★Sell
Current$5.96
Nov 1, 2026

Mobileye offers significant long-term opportunities in advanced driving systems and autonomous mobility, but weak pricing trends, uneven revenue growth, and uncertain returns from robotics investments undermine near-term investment confidence.

Score
62
Alexandria Real Estate Equities, Inc.
ARE·Real Estate
C ★★Sell
Current$39.91
Oct 29, 2026

Alexandria Real Estate Equities offers a potentially deep valuation discount backed by specialized life science properties and substantial liquidity, but persistent vacancy, declining FFO, and asset impairments threaten its recovery.

Score
62
AeroVironment, Inc.
AVAV·Industrials
C ★★Sell
Current$153.40
Sep 15, 2026

AeroVironment is an advantaged defense-drone and counter-UAS platform with record backlog and major laser wins, but acquisition dilution, weak free cash flow, recent control failures and a demanding valuation keep risk-reward unattractive.

Score
62
Grupo Cibest S.A.
CIB·Financials
C ★★Sell
Current$91.99
Nov 12, 2026

Grupo Cibest offers a profitable Colombian banking franchise, strong digital reach, and meaningful dividends, but elevated book-value multiples and rising credit provisions weaken its risk-adjusted investment appeal.

Score
61